Top Page
Qyuns Therapeutics Co., Ltd. Class H
(2509)
Qyuns Therapeutics Co., Ltd. Class H (2509) vs. iShares MSCI Hong Kong ETF (EWH)
Qyuns Therapeutics Co., Ltd. Class H Business Overview & Revenue Model
Qyuns Therapeutics Co., Ltd. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 320.36M | 158.79M | 14.75M | 9.66M | 21.35M |
| Gross Profit | 232.06M | 92.19M | 14.75M | -25.85M | -9.56M |
| EBITDA | -156.69M | -311.82M | -484.12M | -295.51M | -155.65M |
| Net Income | -191.79M | -335.57M | -507.75M | -298.19M | -411.04M |
Balance Sheet | |||||
| Total Assets | 1.13B | 983.88M | 795.58M | 1.16B | 1.31B |
| Cash, Cash Equivalents and Short-Term Investments | 558.90M | 556.55M | 377.25M | 689.57M | 620.44M |
| Total Debt | 635.93M | 527.60M | 346.06M | 295.25M | 290.26M |
| Total Liabilities | 916.32M | 762.83M | 494.63M | 419.55M | 444.45M |
| Stockholders Equity | 226.36M | 228.98M | 324.54M | 641.72M | 670.35M |
Cash Flow | |||||
| Free Cash Flow | -213.39M | -186.09M | -308.63M | -301.70M | -228.64M |
| Operating Cash Flow | -211.00M | -186.09M | -300.68M | -275.23M | -157.60M |
| Investing Cash Flow | 109.12M | -25.23M | 243.11M | -5.70M | -306.69M |
| Financing Cash Flow | 133.17M | 351.81M | 61.21M | 211.49M | 281.48M |
Qyuns Therapeutics Co., Ltd. Class H Technical Analysis
Qyuns Therapeutics Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | HK$1.54B | 189.52 | 0.99% | ― | 9.41% | -32.69% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | HK$2.67B | -2.57 | ― | ― | 79.98% | -3.40% | |
| ― | HK$6.61B | ― | -64.62% | ― | ― | ― | |
| ― | HK$1.05B | ― | ― | ― | ― | 83.89% | |
| ― | HK$1.35B | -4.32 | -34.18% | ― | -57.84% | 24.58% | |
| ― | HK$1.57B | ― | -51.56% | ― | 2.45% | 2.58% |
Qyuns Therapeutics Co., Ltd. Class H Corporate Events
Qyuns Therapeutics Co., Ltd. has entered into a global exclusive license agreement with Roche, granting Roche the rights to develop, manufacture, and commercialize QX031N. This agreement includes an upfront payment of $75 million to Qyuns and potential milestone payments up to $995 million, along with tiered royalties on future sales. The collaboration is expected to enhance Qyuns’ industry positioning by advancing QX031N as a potential ‘First-in-class’ and ‘Best-in-disease’ therapy for respiratory diseases, potentially impacting stakeholders positively with significant financial and market opportunities.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$24.50 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
Qyuns Therapeutics Co., Ltd. has announced successful Phase III clinical trial results for Crusekitug (QX002N), a treatment for ankylosing spondylitis, presented at the 2025 ACR Annual Meeting. The trial demonstrated significant improvements in clinical symptoms and spinal function, with Crusekitug showing a higher ASAS40 response rate compared to placebo, and favorable safety outcomes. These results position Crusekitug as a promising new treatment option, with the company planning to expedite its registration and market launch.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$24.50 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
Qyuns Therapeutics Co., Ltd. announced that its subsidiary, Jiangsu Cellularforce Biopharma Co., Ltd., has successfully passed the EU Qualified Person (QP) audit, meeting the EU GMP standards. This achievement marks a significant milestone in the company’s global expansion strategy, enabling its products to enter the EU market and strengthening its international market presence.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$32.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
Qyuns Therapeutics Co., Ltd. has successfully completed the placement of 5,000,000 new H Shares under a general mandate, with TruMed Health Innovation Fund LP acquiring the shares at HK$20.0 each. This transaction represents approximately 2.20% of the company’s issued shares post-placement, enhancing its capital base and potentially strengthening its market position. TruMed, a Cayman Islands-based investment fund, is a significant player in healthcare equities, and its involvement may signal confidence in Qyuns Therapeutics’ future prospects.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$26.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
Qyuns Therapeutics Co., Ltd. has entered into a Placing Agreement to issue 5,000,000 new H Shares at HK$20.0 per share, representing approximately 2.25% of the company’s issued shares. The shares will be placed with TruMed Health Innovation Fund LP, a healthcare-focused investment fund. The placement is expected to raise gross proceeds of approximately HK$100.0 million, with net proceeds earmarked for strategic allocation. The transaction is conducted under a General Mandate, and no additional shareholder approval is required.
Qyuns Therapeutics Co., Ltd. reported a significant increase in revenue for the first half of 2025, reaching RMB206.49 million, primarily driven by licensing agreements and R&D services. Despite a loss of RMB30.93 million, the company showed an improvement from the previous year, with a notable decrease in adjusted loss, reflecting a positive trend in its financial performance and strategic advancements in clinical trials.
Qyuns Therapeutics Co., Ltd., a joint stock company incorporated in China, has designated Mr. Fung Che Wai, Anthony as the lead independent non-executive director to enhance corporate governance. This move aligns with the amended Corporate Governance Code effective from July 2025, aiming to improve board effectiveness and communication between directors and shareholders.
Qyuns Therapeutics Co., Ltd. has announced the advancement of its product QX004N into Phase III clinical trials, marking it as the fourth product in their pipeline to reach this stage. This milestone has triggered a payment of RMB58.0 million from Hansoh Pharma, as per their licensing agreement, which covers the research, development, manufacturing, and commercialization of QX004N in several regions including mainland China and Hong Kong. This development signifies a significant step forward in the company’s operations and strengthens its position in the pharmaceutical industry.
Qyuns Therapeutics Co., Ltd., a company incorporated in the People’s Republic of China, has announced that its board of directors will hold a meeting on August 15, 2025. The meeting will focus on approving the interim results for the first half of 2025, considering the recommendation of an interim dividend, and addressing other business matters. This announcement indicates the company’s ongoing commitment to transparency and shareholder engagement, potentially impacting investor confidence and market positioning.